Table 2.
Patient No. | aGVHD (Grade/Site) | cGVHD (Grade/Site) | Treatment | Outcome |
---|---|---|---|---|
1 | II/skin | Limited/skin | CsA/pred | resolved |
9 | III/skin | Extensive/lung, liver | CsA/Pred | Died of GVHD |
27 | None | Limited/skin | none | resolved |
30 | III/skin, GI, liver | Extensive/GI, liver | CsA/Pred/ATG/thalidomide | Died of GVHD |
34 | III/skin, GI, liver | Limited/oral | CsA/Pred | resolved |
35 | III/skin, GI, liver | Extensive/skin, liver, GI | CsA/tacrolimus/MMF/ATG/OKT3/sirolimus | resolved |
41 | III/skin | Extensive/skin, lung, oral | Tacrolimus/pred/MMF/azathioprine | Died of GVHD |
51 | II/skin | Limited/skin | CsA/pred | resolved |
aGVHD indicates acute graft-versus-host disease; ATG, antithymocyte globulin; BMT, bone marrow transplantation; cGVHD, chronic graft-versus-host disease; CsA, cyclosporine; GI, gastrointestinal; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; Pred, prednisone.